roon schreef op 3 oktober 2023 13:45:
Gooi er dit maar uit pharming;
Point Biopharma Shares Surge Premarket on Takeover by Eli Lilly
< 1 minuten geleden (vandaag 13:43:41)
Dow Jones Newswires
By Colin Kellaher
Shares of Point Biopharma Global took flight in premarket trading Tuesday after the radiopharmaceutical company agreed to be acquired by drugmaker Eli Lilly at a rich premium.
Eli Lilly said it will pay $1.4 billion, or $12.50 a share, in cash for Point, 87% above Monday's closing price of $6.68.
Eli Lilly, which has been building up its oncology arm around its $8 billion acquisition of cancer-drug developer Loxo Oncology in 2019, said the deal adds next-generation radioligand therapies, along with a 180,000-square-foot radiopharmaceutical manufacturing campus in its hometown of Indianapolis.
Radioligand therapy is a targeted form of cancer treatment that delivers radiation directly to cancer cells, helping to limit damage to healthy, surrounding tissue.
Point has a pipeline of clinical and preclinical-stage radioligand therapies, with lead programs in late-phase development for prostate cancer and gastroenteropancreatic neuroendocrine tumors.